# Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Source: https://onco.cc/trials/nct07288359/  
OnCo record `nct07288359` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Fulvestrant, Letrozole in prostate cancer, run by Novartis Pharmaceuticals, now recruiting.

## Summary

Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07288359 by Novartis Pharmaceuticals, with 205 participants planned, started 2025-12-29 and due to reach its primary completion in 2031-05-09. Interventions recorded: GVV858, Fulvestrant, Letrozole. Conditions listed: Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Metastatic Castration-resistant Prostate Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07288359
- Phase: 1/2
- Setting: An Open-label, Multi-center, Phase I/II Study of GVV858 as a Single Agent and in Combination With Endocrine Therapy in Patients With Advanced Hormone Receptor Positive, HER2- Negative Breast Cancer and Other Advanced Solid Tumors
- Sponsor: Novartis Pharmaceuticals
- Enrolled: 205

## Sources

- ClinicalTrials.gov NCT07288359: https://clinicaltrials.gov/study/NCT07288359

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- drugs: [Fulvestrant](https://onco.cc/drugs/fulvestrant/), [Letrozole (and other aromatase inhibitors)](https://onco.cc/drugs/letrozole/)
- companies: [Novartis](https://onco.cc/companies/novartis/)

---
JSON: https://onco.cc/api/v1/entities/nct07288359.json